...
首页> 外文期刊>Integrative cancer therapies >Chemopreventive effect of Curcuma longa Linn on liver pathology in HBx transgenic mice.
【24h】

Chemopreventive effect of Curcuma longa Linn on liver pathology in HBx transgenic mice.

机译:姜黄对HBx转基因小鼠肝病理的化学预防作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Unlike other forms of hepatocellular carcinoma (HCC), HCC induced by hepatitis B virus (HBV) infection shows a poor prognosis after conventional therapies. HBV induces liver cirrhosis and HCC. Many researchers have made efforts to find new substances that suppress the activity of HBV. Curcuma longa Linn (CLL) has been used for traditional medicine and food in Asia, especially in India, and has shown chemopreventive effects in a HBV-related in vitro model. This in vivo study was designed to seek the chemopreventive effects of CLL and its mechanisms. CLL mixture concentrated with dextrose water by boiling was lyophilized. CLL extracts were administrated to HBV X protein (HBx) transgenic mice aged 4 weeks for 2 to 4 weeks and aged 6 months for 3 months. After administration, histological changes in the liver tissue and expression of HBx-related genes were investigated. CLL-treated mice showed less visceral fat, a smaller liver/body weight ratio and delayed liver pathogenesis. Proliferating cell nuclear antigen (PCNA) expression was also increased in CLL-treated HBx transgenic mice, indicating regeneration of damaged liver tissue. CLL treatment decreased expression of HBx and increased p21 and cyclin D1 in livers of HBx transgenic mice. In addition, p-p53 was increased after CLL treatment. These results suggest that CLL can have beneficial effects on the early and late stages of liver pathogenesis, preventing and delaying liver carcinogenesis. This drug should be considered as a potential chemopreventive agent for HBV-related hepatocarcinogenesis.
机译:与其他形式的肝细胞癌(HCC)不同,乙型肝炎病毒(HBV)感染诱导的HCC在常规治疗后预后较差。乙肝病毒会诱发肝硬化和肝癌。许多研究人员已努力寻找抑制HBV活性的新物质。姜黄(Curcuma longa Linn)(CLL)在亚洲,尤其是在印度已用于传统医学和食品,并且在与HBV有关的体外模型中显示出化学预防作用。这项体内研究旨在寻找CLL的化学预防作用及其机制。将通过沸腾用葡萄糖水浓缩的CLL混合物冻干。将CLL提取物施用于4周龄2至4周和6个月龄3个月的HBV X蛋白(HBx)转基因小鼠。给药后,研究肝组织的组织学变化和HBx相关基因的表达。用CLL治疗的小鼠显示出较少的内脏脂肪,较小的肝脏/体重比和延迟的肝发病机理。在CLL处理的HBx转基因小鼠中,增殖细胞核抗原(PCNA)的表达也增加,表明受损肝组织的再生。 CLL处理可降低HBx转基因小鼠肝脏中HBx的表达,并增加p21和cyclin D1。另外,CLL处理后p-p53增加。这些结果表明,CLL可对肝发病机理的早期和晚期产生有益的作用,预防和延缓肝癌的发生。该药物应被视为与HBV相关的肝癌发生的潜在化学预防剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号